Genmab ( ($GMAB) ) just unveiled an update. On August 13, 2025, Genmab A/S announced updates to its Articles of Association, including ...

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Genmab (Otc) (($GMAB)) has held its Q2 earnings call. Read on for the main highlights of the call. Genmab’s recent earnings call reflects a ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in ...

Genmab raised its full-year revenue and profit guidance on Thursday, driven by stronger-than-expected royalties from key ...

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in follicular lymphoma (FL). | Genmab and AbbVie have presented new data that could ...

Genmab and AbbVie’s Epkinly has met its dual primary endpoints as a second-line combination therapy in relapsed/refractory ...

Genmab AS (GMAB) reports a 19% revenue increase and a 56% rise in operating profit, showcasing strong financial performance ...

Copenhagen, Denmark Saturday, August 9, 2025, 13:00 Hrs [IST] ...

Genmab shares were 6% higher, at $22.72 a share, after the company reported positive results of a Phase 3 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide in ...